# Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study

> **NCT07482670** · — · NOT_YET_RECRUITING · sponsor: **Xiangya Hospital of Central South University** · enrollment: 32 (estimated)

## Conditions studied

- Hepatecellular Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07482670
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07482670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07482670, "Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07482670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*